Glimisave MV 1 Tablet SR is a combination oral hypoglycemic agent formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, each contributing distinct mechanisms to optimize blood glucose regulation. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, which improves glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, resulting in a reduction of postprandial hyperglycemia. The sustained-release (SR) formulation ensures a gradual release of active ingredients, promoting better patient compliance and minimizing gastrointestinal side effects commonly associated with metformin. Glimisave MV 1 is indicated as an adjunct to diet and exercise for the management of type 2 diabetes when monotherapy is inadequate. It should be used under medical supervision with regular monitoring of blood glucose levels, renal function, and potential adverse effects such as hypoglycemia and gastrointestinal disturbances. Dose adjustments may be necessary based on therapeutic response and tolerability.